Literature DB >> 16794206

Frequency, management, and predictors of abnormal mood after stroke: the Auckland Regional Community Stroke (ARCOS) study, 2002 to 2003.

Maree L Hackett1, Craig S Anderson.   

Abstract

BACKGROUND AND
PURPOSE: Mood disorders are an important consequence of stroke. We aimed to identify significant, clinically useful predictors of abnormal mood after stroke.
METHODS: The Auckland Regional Community Stroke (ARCOS) study was a prospective population-based stroke incidence study conducted in Auckland, New Zealand, over a 12-month period from 2002 to 2003. All patients were followed up 6 months after stroke onset and abnormal mood was assessed using the 28-item General Health Questionnaire (GHQ-28) administered as part of a structured telephone interview. Multivariate stepwise logistic regression was used to develop a predictive model for "caseness" (score of > or = 5 on the GHQ-28) based on several premorbid patient and clinical variables assessed at baseline and 28 days of follow up.
RESULTS: Of patients available at 6 months (n=1172), complete data on mood was available from 739 (60%) patients and 27% (95% confidence interval, 24 to 30%) were defined as cases. Key baseline predictors of abnormal mood were disability and history of depression after adjustment for sex, age, and comorbidity, but the model failed to predict a large amount of the variation in caseness (C statistic 0.587).
CONCLUSIONS: This study emphasizes the complex nature of mood disturbance after stroke and that multiple factors are likely to contribute to mood disorders. A simple, clinically applicable, predictive model in stroke care appears difficult to develop.

Entities:  

Mesh:

Year:  2006        PMID: 16794206     DOI: 10.1161/01.STR.0000231387.58943.1f

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  8 in total

Review 1.  Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke.

Authors:  F Chollet; J Rigal; P Marque; M Barbieux-Guillot; N Raposo; V Fabry; J F Albucher; J Pariente; I Loubinoux
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-23       Impact factor: 5.081

2.  Association of serotonin transporter gene polymorphisms with poststroke depression.

Authors:  Ruth Kohen; Kevin C Cain; Pamela H Mitchell; Kyra Becker; Ann Buzaitis; Steven P Millard; Grace P Navaja; Linda Teri; David Tirschwell; Richard Veith
Journal:  Arch Gen Psychiatry       Date:  2008-11

Review 3.  Use of antidepressant medications to improve outcomes after stroke.

Authors:  F Chollet; B Acket; N Raposo; J F Albucher; I Loubinoux; J Pariente
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

4.  The lived experience of stroke survivors with early depressive symptoms: A longitudinal perspective.

Authors:  Siren E Kouwenhoven; Marit Kirkevold; Knut Engedal; Stian Biong; Hesook S Kim
Journal:  Int J Qual Stud Health Well-being       Date:  2011-12-07

5.  Association among depression, cognitive impairment and executive dysfunction after stroke.

Authors:  Luisa Terroni; Matildes F M Sobreiro; Adriana B Conforto; Carla C Adda; Valeri D Guajardo; Mara Cristina S de Lucia; Renério Fráguas
Journal:  Dement Neuropsychol       Date:  2012 Jul-Sep

6.  Factors influencing the amount of therapy received during inpatient stroke care: an analysis of data from the UK Sentinel Stroke National Audit Programme.

Authors:  Matthew Gittins; Andy Vail; Audrey Bowen; David Lugo-Palacios; Lizz Paley; Benjamin Bray; Brenda Gannon; Sarah Tyson
Journal:  Clin Rehabil       Date:  2020-06-07       Impact factor: 3.477

7.  Psychosocial Outcomes in StrokE: the POISE observational stroke study protocol.

Authors:  Maree L Hackett; Nick Glozier; Stephen Jan; Richard Lindley
Journal:  BMC Neurol       Date:  2009-06-12       Impact factor: 2.474

8.  Sustained inflammation 1.5 years post-stroke is not associated with depression in elderly stroke survivors.

Authors:  Kate Noonan; Sheila G Crewther; Leeanne M Carey; Michaela C Pascoe; Thomas Linden
Journal:  Clin Interv Aging       Date:  2013-01-22       Impact factor: 4.458

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.